Sonde Health, a PureTech Health spinout company that creates vocal biomarker technology, today announced it’s collaborating with wireless technology company Qualcomm Technologies.
The partnership will integrate Sonde’s machine learning vocal biomarker capabilities with Qualcomm’s Snapdragon 888 and 778G 5G mobile platforms to bring health screening and monitoring applications to mobile devices that use these platforms.
Sonde’s lead product, Sonde One, can detect asthma, COPD, COVID-19, depression, and anxiety with only a six-second voice sample. Through this collaboration, device makers can enable vocal biomarker monitoring as a device feature that users can opt-in for.
The hope is that users can receive faster and more secure results because their mobile devices already have the capability to monitor their vocal biomarkers built-in.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“Imagine a car that can detect whether a driver is too impaired to drive safely or a home hub that can detect the onset of depression, or a phone that can make continuous asthma assessments,” David Liu, CEO at Sonde Health, said in a statement.
“Bringing the vocal biomarker technology directly into mobile hardware will make new health features more useful and secure. This collaboration marks a tremendous boost to our growth strategy, a vote of confidence in our technology, and a giant leap forward for preventive and personalized health care.”
Source: Mobihealthnews